Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
Public ClinicalTrials.gov record NCT06914908. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 148 weeks per participant, including 144 weeks of treatment period and 4 weeks of follow-up.
Study identification
- NCT ID
- NCT06914908
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 11, 2025
- Primary completion
- Jan 28, 2031
- Completion
- Jan 28, 2031
- Last update posted
- Jul 1, 2026
2025 – 2031
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Modena Allergy + Asthma- Site Number : 8400005 | La Jolla | California | 92037 | — |
| Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003 | Roseville | California | 95661 | — |
| Treasure Valley Medical Research- Site Number : 8400002 | Boise | Idaho | 83706 | — |
| Essential Medical Research- Site Number : 8400020 | Tulsa | Oklahoma | 74137 | — |
| McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017 | Bellaire | Texas | 77401 | — |
| Pharmaceutical Research & Consulting- Site Number : 8400004 | Dallas | Texas | 75231 | — |
| ENT Associates of Texas - McKinne- Site Number : 8400014 | McKinney | Texas | 75070 | — |
| Alamo ENT Associates- Site Number : 8400001 | San Antonio | Texas | 78258 | — |
| Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008 | Norfolk | Virginia | 23510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06914908, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06914908 live on ClinicalTrials.gov.